CN100509801C - 抑制hiv的嘧啶衍生物 - Google Patents

抑制hiv的嘧啶衍生物 Download PDF

Info

Publication number
CN100509801C
CN100509801C CNB028159209A CN02815920A CN100509801C CN 100509801 C CN100509801 C CN 100509801C CN B028159209 A CNB028159209 A CN B028159209A CN 02815920 A CN02815920 A CN 02815920A CN 100509801 C CN100509801 C CN 100509801C
Authority
CN
China
Prior art keywords
alkyl
formula
compound
cyano
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028159209A
Other languages
English (en)
Chinese (zh)
Other versions
CN1541215A (zh
Inventor
J·E·G·古勒蒙特
P·帕兰德吉安
M·R·德乔格
L·M·H·科伊曼斯
H·M·温克斯
F·F·D·达雅尔特
J·赫勒斯
K·J·A·范亚肯
P·J·勒维
P·A·J·詹森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100509801(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1541215A publication Critical patent/CN1541215A/zh
Application granted granted Critical
Publication of CN100509801C publication Critical patent/CN100509801C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028159209A 2001-08-13 2002-08-09 抑制hiv的嘧啶衍生物 Expired - Lifetime CN100509801C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01203090 2001-08-13
EP01203090.4 2001-08-13
EP02077748.8 2002-06-10
EP02077748 2002-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910145401.5A Division CN101816658B (zh) 2001-08-13 2002-08-09 抑制hiv的嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN1541215A CN1541215A (zh) 2004-10-27
CN100509801C true CN100509801C (zh) 2009-07-08

Family

ID=26076978

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028159209A Expired - Lifetime CN100509801C (zh) 2001-08-13 2002-08-09 抑制hiv的嘧啶衍生物
CN200910145401.5A Expired - Lifetime CN101816658B (zh) 2001-08-13 2002-08-09 抑制hiv的嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910145401.5A Expired - Lifetime CN101816658B (zh) 2001-08-13 2002-08-09 抑制hiv的嘧啶衍生物

Country Status (37)

Country Link
US (8) US7125879B2 (cs)
EP (3) EP3808743B1 (cs)
JP (4) JP2005507380A (cs)
KR (2) KR100969273B1 (cs)
CN (2) CN100509801C (cs)
AP (1) AP1610A (cs)
AR (1) AR036387A1 (cs)
AT (1) ATE517891T1 (cs)
AU (1) AU2002329238C1 (cs)
BE (3) BE2012C020I2 (cs)
BR (3) BR122015023612B8 (cs)
CA (1) CA2452217C (cs)
CY (4) CY1112331T1 (cs)
DE (1) DE122012000038I1 (cs)
DK (2) DK1419152T3 (cs)
EA (1) EA006656B1 (cs)
EG (1) EG24684A (cs)
ES (3) ES2923581T3 (cs)
FR (3) FR12C0035I2 (cs)
HR (3) HRP20120265B1 (cs)
HU (5) HU230192B1 (cs)
IL (2) IL160328A0 (cs)
JO (1) JO3429B1 (cs)
LT (3) LT3808743T (cs)
LU (2) LU92001I2 (cs)
MX (1) MXPA04001401A (cs)
MY (1) MY189572A (cs)
NO (3) NO327639B1 (cs)
NZ (1) NZ530951A (cs)
OA (1) OA12652A (cs)
PA (1) PA8552901A1 (cs)
PL (2) PL402388A1 (cs)
PT (1) PT1419152E (cs)
SI (2) SI3808743T1 (cs)
UA (1) UA78221C2 (cs)
WO (1) WO2003016306A1 (cs)
ZA (1) ZA200401159B (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
WO2004014382A1 (en) 2002-07-29 2004-02-19 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EA007953B1 (ru) * 2002-08-09 2007-02-27 Янссен Фармацевтика Н.В. Способы получения 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CN102503903A (zh) * 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
HRP20050688B1 (hr) * 2003-02-07 2017-03-24 Janssen Pharmaceutica N.V. Derivati pirimidina za sprječavanje hiv infekcije
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
DK1648467T3 (en) 2003-07-17 2018-06-25 Janssen Sciences Ireland Uc PROCEDURE FOR MANUFACTURING PARTICLES CONTAINING AN ANTIVIRUS AGENT
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) * 2003-09-03 2012-06-11 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8026245B2 (en) * 2003-09-25 2011-09-27 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
EP1781639B1 (en) 2004-07-28 2012-01-25 Janssen Pharmaceutica NV Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
ATE540677T1 (de) 2004-08-25 2012-01-15 Ardea Biosciences Inc S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
ES2371923T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
CA2573976C (en) * 2004-09-30 2014-04-29 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
ATE542802T1 (de) * 2004-09-30 2012-02-15 Tibotec Pharm Ltd Hiv-inhibierende 5-substituierte pyrimidine
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
PT1888537E (pt) * 2005-05-26 2013-11-26 Janssen R & D Ireland Processo para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)amino benzonitrilo
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
WO2007113256A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
RU2480464C2 (ru) 2006-03-30 2013-04-27 Тиботек Фармасьютикалз Лтд. 5-амидо-замещенные пиримидины, ингибирующие вич
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
UY30431A1 (es) * 2006-06-23 2008-01-31 Tibotec Pharm Ltd Suspensiones acuosas de tmc278
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
BRPI0718592A2 (pt) 2006-11-09 2017-06-06 Ardea Biosciences Inc compostos heterocíclicos bicíclicos substituidos por 4-cianofenilamino como inibidores de hiv
MY148427A (en) 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101553483B (zh) * 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
CN101573343B (zh) 2006-12-29 2016-02-24 爱尔兰詹森科学公司 抑制人免疫缺陷病毒的6-取代的嘧啶
ES2618057T3 (es) 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
CA2677096A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
ES2542153T3 (es) 2007-05-30 2015-07-31 F. Hoffmann-La Roche Ag Inhibidores no nucleósidos de la transcriptasa inversa
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
JP5701057B2 (ja) * 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー （ｅ）４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの結晶形
CN101407476B (zh) * 2007-10-12 2012-07-18 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
AR069753A1 (es) 2007-11-27 2010-02-17 Ardea Biosciences Inc Compuestos de 1,2,4-triazol y composiciones, utiles en la modulacion de los niveles de acido urico sanguineo
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2732765A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
CN101717364B (zh) * 2008-10-09 2014-08-13 中国人民解放军军事医学科学院毒物药物研究所 作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
US8933106B2 (en) 2008-10-09 2015-01-13 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 2-(4-substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
SG196774A1 (en) 2008-12-24 2014-02-13 Tibotec Pharm Ltd Implantable devices for treating hiv
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
WO2011094273A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
SI2531027T1 (sl) * 2010-01-27 2015-08-31 Viiv Healthcare Company Terapevtska kombinacija, ki obsega dolutegravir, abakavir in lamivudin
EP2536696A1 (en) * 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
WO2012021444A1 (en) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
MY181898A (en) 2010-11-01 2021-01-12 Celgene Car Llc Heterocyclic compounds and uses thereof
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
BR112013012245B1 (pt) 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2012147091A2 (en) 2011-04-25 2012-11-01 Hetero Research Foundation Process for rilpivirine
HRP20170928T1 (hr) 2011-08-30 2017-09-22 Chdi Foundation, Inc. Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
ES2680146T3 (es) 2011-09-16 2018-09-04 Hetero Research Foundation Hidrocloruro de rilpivirina
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
SG10201700799WA (en) 2012-03-15 2017-02-27 Celgene Avilomics Res Inc Salts of an epidermal growth factor receptor kinase inhibitor
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
US9139535B2 (en) * 2012-07-12 2015-09-22 Hetero Research Foundation Process for rilpivirine using novel intermediate
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106715421A (zh) * 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10092523B2 (en) 2014-09-26 2018-10-09 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
US20170000807A1 (en) 2015-06-30 2017-01-05 Gilead Sciences, Inc. Pharmaceutical formulations
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) * 2016-07-04 2018-08-21 宜昌人福药业有限责任公司 一种有效去除利匹韦林异构体的方法
WO2018077815A1 (en) 2016-10-24 2018-05-03 Janssen Sciences Ireland Uc Dispersible compositions
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) * 2016-12-08 2018-12-25 西北师范大学 一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) * 2017-02-27 2019-08-16 武汉工程大学 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
AU2018291076B2 (en) 2017-06-30 2021-01-21 Janssen Sciences Ireland Unlimited Company Combination and uses and treatments thereof
CN112996795B (zh) 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
CN109293581B (zh) * 2018-09-21 2020-03-27 宜昌人福药业有限责任公司 一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
EP3870568B1 (en) 2018-10-25 2023-06-28 Minakem Process for the preparation of rilpivirine
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
WO2022000019A1 (en) * 2020-06-30 2022-01-06 University Of South Australia New therapeutic use of rilpivirine
CN112028836B (zh) * 2020-09-09 2021-12-07 山东大学 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) * 2021-03-08 2021-07-13 复旦大学 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) * 2021-05-06 2021-10-01 复旦大学 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) * 2021-09-03 2021-12-28 复旦大学 一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
KR20240095514A (ko) 2021-11-17 2024-06-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 용해도 평가
WO2023203258A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Liquid compositions
WO2023203255A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
WO2023222755A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CN115490642B (zh) * 2022-09-21 2024-11-15 山东大学 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
CN1295564A (zh) * 1998-03-27 2001-05-16 詹森药业有限公司 抑制hiv的嘧啶衍生物
CN1322198A (zh) * 1998-11-10 2001-11-14 詹森药业有限公司 抑制hiv复制的嘧啶类

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3953398A (en) * 1970-07-20 1976-04-27 The Goodyear Tire & Rubber Company Age resistant polymeric compositions
JPS63159316A (ja) * 1977-11-28 1988-07-02 アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド 中性銅結合体を含む抗炎症組成物
EP0002341B1 (en) * 1977-11-28 1982-01-20 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5879920A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 血小板凝集阻害剤
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP3990808B2 (ja) * 1998-03-26 2007-10-17 Ｔｄｋ株式会社 非水電解質電池用電極の製造方法
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
JP2000035628A (ja) * 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
WO2000012485A1 (en) * 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
EP1159279B1 (en) 1999-03-09 2002-10-16 PHARMACIA & UPJOHN COMPANY 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1282606B1 (en) 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replication inhibiting pyrimidines and triazines
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CN1494528A (zh) * 2001-03-02 2004-05-05 ʷ��˿�������ȳ�ķ���޹�˾ 作为逆转录酶抑制剂的二苯酮
US6949544B2 (en) * 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
EP1427366A2 (en) * 2001-08-29 2004-06-16 UMD, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003222310B2 (en) * 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
EA007953B1 (ru) 2002-08-09 2007-02-27 Янссен Фармацевтика Н.В. Способы получения 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
HRP20050688B1 (hr) * 2003-02-07 2017-03-24 Janssen Pharmaceutica N.V. Derivati pirimidina za sprječavanje hiv infekcije
US9226970B2 (en) * 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
CN1295564A (zh) * 1998-03-27 2001-05-16 詹森药业有限公司 抑制hiv的嘧啶衍生物
CN1322198A (zh) * 1998-11-10 2001-11-14 詹森药业有限公司 抑制hiv复制的嘧啶类

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
US11571422B2 (en) 2019-11-29 2023-02-07 Scipio Life Sciences Limited Composition including rilpivirine and method for treating tumors or cancer
US12023334B2 (en) 2019-11-29 2024-07-02 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Also Published As

Publication number Publication date
CY2012012I1 (el) 2015-08-05
HRP20040096B1 (hr) 2013-06-30
JP2011225589A (ja) 2011-11-10
HRP20120265A2 (hr) 2012-05-31
KR100817453B1 (ko) 2008-03-27
HUS1500055I1 (hu) 2016-03-29
PL368270A1 (en) 2005-03-21
EP2298761A1 (en) 2011-03-23
JO3429B1 (ar) 2019-10-20
US20170320835A1 (en) 2017-11-09
HK1145449A1 (en) 2011-04-21
BRPI0211909B8 (pt) 2021-05-25
LTC3808743I2 (cs) 2023-04-25
HUP0401346A3 (en) 2009-03-02
CA2452217A1 (en) 2003-02-27
US20170121292A1 (en) 2017-05-04
OA12652A (en) 2006-06-15
WO2003016306A1 (en) 2003-02-27
US20120076835A1 (en) 2012-03-29
US10611732B2 (en) 2020-04-07
EG24684A (en) 2010-05-05
BRPI0211909B1 (pt) 2018-05-29
HRP20120265B1 (hr) 2019-11-29
MXPA04001401A (es) 2004-05-27
SI3808743T1 (sl) 2022-09-30
US20140343006A1 (en) 2014-11-20
CY2012012I2 (el) 2015-08-05
FR12C0036I2 (fr) 2016-05-06
CN1541215A (zh) 2004-10-27
HU230192B1 (hu) 2015-09-28
EP3808743A1 (en) 2021-04-21
HRP20192051B1 (hr) 2022-05-27
ES2368996T3 (es) 2011-11-24
HU231274B1 (hu) 2022-07-28
JP2011236221A (ja) 2011-11-24
CN101816658B (zh) 2014-08-27
ATE517891T1 (de) 2011-08-15
NO20040633L (no) 2004-03-12
EP1419152A1 (en) 2004-05-19
HRP20192051A2 (hr) 2020-03-06
FR12C0036I1 (cs) 2012-06-29
HRP20040096A2 (en) 2004-06-30
EP3808743B1 (en) 2022-07-20
US9580392B2 (en) 2017-02-28
CY2022024I1 (el) 2023-01-05
AR036387A1 (es) 2004-09-08
IL160328A0 (en) 2004-07-25
AU2002329238B2 (en) 2008-01-24
DE122012000038I1 (de) 2012-09-20
FR12C0035I1 (cs) 2012-06-22
BR0211909A (pt) 2004-08-24
BR122015023612B1 (pt) 2021-01-19
EA200400304A1 (ru) 2004-08-26
BE2012C020I2 (cs) 2021-07-19
CY2012013I2 (el) 2015-08-05
AP1610A (en) 2006-05-08
NO327639B1 (no) 2009-09-07
BE2012C022I2 (cs) 2022-01-12
CY2022024I2 (el) 2023-01-05
SI1419152T1 (sl) 2011-11-30
AU2002329238C1 (en) 2008-08-28
ES2799408T3 (es) 2020-12-17
EP1419152B1 (en) 2011-07-27
EA006656B1 (ru) 2006-02-24
BR122015032641B1 (pt) 2022-03-03
HUP0401346A2 (hu) 2004-12-28
DK1419152T3 (da) 2011-10-24
LTC1419152I2 (lt) 2025-05-12
US7125879B2 (en) 2006-10-24
UA78221C2 (uk) 2007-03-15
FR12C0035I2 (fr) 2016-02-12
JP5247661B2 (ja) 2013-07-24
LU92001I2 (fr) 2012-07-16
NO2012010I1 (no) 2012-06-18
NO20083770L (no) 2004-03-12
EP2298761B1 (en) 2020-03-25
PL216398B1 (pl) 2014-03-31
US8080551B2 (en) 2011-12-20
CY2012013I1 (el) 2015-08-05
US9981919B2 (en) 2018-05-29
CY1112331T1 (el) 2015-08-05
FR22C1036I1 (fr) 2022-09-09
US20040198739A1 (en) 2004-10-07
KR100969273B1 (ko) 2010-08-20
LU92008I2 (fr) 2012-07-24
PT1419152E (pt) 2011-10-11
JP5539927B2 (ja) 2014-07-02
HUS1500051I1 (hu) 2018-05-28
PA8552901A1 (es) 2003-02-28
JP4838396B2 (ja) 2011-12-14
HUS2200038I1 (hu) 2022-08-28
KR20040023645A (ko) 2004-03-18
DK3808743T3 (da) 2022-08-01
LT3808743T (lt) 2022-08-10
US20180244632A1 (en) 2018-08-30
US10370340B2 (en) 2019-08-06
BR122015023612B8 (pt) 2021-05-25
AP2004002993A0 (en) 2004-03-31
PL402388A1 (pl) 2013-04-02
LTPA2022515I1 (cs) 2022-08-25
IL160328A (en) 2011-01-31
NO2012010I2 (no) 2013-09-02
CN101816658A (zh) 2010-09-01
HK1070066A1 (en) 2005-06-10
NO337142B1 (no) 2016-02-01
BE2022C531I2 (cs) 2022-08-09
LTPA2012008I1 (lt) 2012-06-25
US20190322628A1 (en) 2019-10-24
JP2005507380A (ja) 2005-03-17
MY189572A (en) 2022-02-17
KR20070101409A (ko) 2007-10-16
CA2452217C (en) 2009-06-16
ES2923581T3 (es) 2022-09-28
NZ530951A (en) 2005-10-28
ZA200401159B (en) 2005-07-27
US20060252764A1 (en) 2006-11-09
JP2010077140A (ja) 2010-04-08

Similar Documents

Publication Publication Date Title
CN100509801C (zh) 抑制hiv的嘧啶衍生物
CN100475815C (zh) 抑制hiv复制的嘌呤衍生物
CN100572364C (zh) 抑制hiv复制的嘧啶和三嗪
CN101031558B (zh) 抑制人类免疫缺陷病毒的5-杂环基嘧啶
CN102503903A (zh) 抑制hiv的1,2,4-三嗪
CN101035773B (zh) 抑制hiv的1,2,4-三嗪-6-酮衍生物
JP5656976B2 (ja) ピロロトリアジン化合物
IL261657A (en) Heterocyclic amides are useful as modulators of protein
CN100554245C (zh) 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
CN102151270A (zh) 预防hiv感染的嘧啶衍生物
CN118063470A (zh) 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
CN101027288B (zh) 抑制hiv的5-取代嘧啶
ES2365015T3 (es) Pirimidinas sustituidas con indano que inhiben la replicación del vih.
HK1070066B (en) Hiv inhibiting pyrimidines derivatives
HK1145449B (en) Hiv inhibiting pyrimidines derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070066

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1070066

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20090708

CX01 Expiry of patent term